

Gunagratinib

Chemical Properties


CAS No. : 2211082-53-8

Formula: C₂₂H₂₅N₅O₄

Molecular Weight: 423.47

Storage: Store at low temperature, Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	Gunagratinib (ICP-192) is an orally active and highly effective pan-FGFR (fibroblast growth factor receptor) inhibitor, used in studies of FGFR-related diseases.
Targets(IC50)	FGFR
In vitro	Gunagratinib is a novel pan-FGFR (fibroblast growth factor receptor) inhibitor that effectively and selectively irreversibly inhibits FGFR activity through covalent binding with antitumor activity. [1]

Solubility Information

Solubility	DMSO: 80 mg/mL (188.92 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3614 mL	11.8072 mL	23.6144 mL
5 mM	0.4723 mL	2.3614 mL	4.7229 mL
10 mM	0.2361 mL	1.1807 mL	2.3614 mL
50 mM	0.0472 mL	0.2361 mL	0.4723 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.

Jisong Cui, et al. Method for treating head and neck cancer. WO2023088105A1. 2022-11-03

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481